0
     

Report Added
Report already added
Stem Cell Therapy Market by Type (Allogeneic, Autologous), Cell Source (Adipose Tissue-derived MSC, Bone Marrow, Placenta/Umbilical Cord), Therapeutic Application (Musculoskeletal, Wounds, Surgeries, Cardiovascular, Neurological) - Global Forecast to 2027

Stem Cell Therapy Market by Type (Allogeneic, Autologous), Cell Source (Adipose Tissue-derived MSC, Bone Marrow, Placenta/Umbilical Cord), Therapeutic Application (Musculoskeletal, Wounds, Surgeries, Cardiovascular, Neurological) - Global Forecast to 2027

The global stem cell therapy market is projected to reach USD 558 million by 2027 from USD 257 million in 2022, at a CAGR of 16.8% during the forecast period. Several companies are focusing on developing regenerative medicine due to the rising number of clinical trials conducted on stem cell therapies. The increasing number of clinical trials has largely taken place owing to the rising government and public & private investments for R&D in cell-based therapies, supportive regulatory framework, and accelerated approval provisions by the FDA in regenerative medicine R&D.

“The allogeneic stem cell therapy segment accounted for the highest growth rate in the stem cell therapy market, by type, during the forecast period”

The stem cell therapy market is segmented into allogeneic and autologous stem cell therapy. Allogeneic stem therapy segment accounted for the largest share of the stem cell therapy market. Stem cells used for allogeneic stem cell therapy are obtained from sources other than the target patient, which is usually from a donor. In allogeneic stem cell therapy, one cell source can produce many doses, thus making allogeneic therapy economically viable and less time-consuming. Moreover, it is easier to scale up production processes for allogeneic therapy than for autologous therapy. Currently, more than ten approved commercialized allogeneic stem cell therapies are available globally.

“Bone Marrow-derived MSCs segment accounted for the highest CAGR”

Based on the cell source the global stem cell therapy market is segmented into adipose tissue-derived MSCs (mesenchymal stem cells), bone marrow-derived MSCs, placenta/umbilical cord-derived MSCs, and other cell sources. Bone marrow-derived mesenchymal stem cells are the most preferred type for stem cell therapies. Bone marrow MSCs are readily available, require less in vitro processing, and can be used for autologous and allogeneic stem cell therapy. Over the last decade, the stem cell therapy market has witnessed high demand for several bone marrow-derived stem cell-based products for various therapeutic applications, including immune-deficiency syndromes, hemoglobinopathies, and metabolic disorders. This has collectively contributed the segment’s growth.

“Asia Pacific: The fastest-growing country in the stem cell therapy market”

The stem cell therapy market is segmented into North America, Europe, Asia Pacific, RoW. The stem cell therapy market in the Asia Pacific region is expected to grow at the highest CAGR during the forecast period. Rising cases of neurodegenerative disorders drive market growth for stem cell therapy products in India along with favorable government support for stem cell therapy products in South Korea have propelled the growth of Asia Pacific stem cell therapy market.

The primary interviews conducted for this report can be categorized as follows:
•By Respondent: Supply Side- 80% and Demand Side 20%
•By Designation: C-level - 25%, D-level - 20%, and Others - 55%
•By Region: North America -50%, Europe -20%, Asia-Pacific -20%, RoW -10%

Lists of Companies Profiled in the Report:
•Smith+Nephew (UK)
•MEDIPOST Co. Ltd. (South Korea)
•Anterogen Co. Ltd. (South Korea)
•CORESTEM (South Korea)
•Pharmicell Co. Ltd. (South Korea)
•NuVasive Inc. (US)
•RTI Surgical (US)
•AlloSource (US)
•JCR Pharmaceuticals Co. Ltd. (Japan)
•Takeda Pharmaceutical Company Limited (Japan)
•Holostem Terapie Avanzate Srl (Italy)
•Orthofix (US)
•Regrow Biosciences Pvt Ltd. (India)
•STEMPEUTICS RESEARCH PVT LTD. (India)
•Athersys (US)
•Mesoblast Ltd (Australia)
•Biorestorative Therapies Inc. (US)
•Pluristem Inc. (Israel)
•Brainstorm Cell Limited. (US)
•ViaCyte Inc. (US)
•Gamida Cell (US)
•Kangstem Biotech (South Korea)
•Hope Biosciences (US)
•Cellular Biomedicine Group (US)
•Personalized Stem Cells (US)

Research Coverage:
This report provides a detailed picture of the stem cell therapy market. It aims at estimating the size and future growth potential of the market across different segments, such as the type, therapeutic applications, and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall stem cell therapy market and its segments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, trends, opportunities, and challenges.
Table of Contents

1INTRODUCTION26
1.1STUDY OBJECTIVES26
1.2MARKET DEFINITION26
1.2.1INCLUSIONS & EXCLUSIONS26
1.3STUDY SCOPE27
FIGURE 1STEM CELL THERAPY MARKET27
1.3.1YEARS CONSIDERED27
1.4CURRENCY CONSIDERED28
1.5LIMITATIONS28
1.6STAKEHOLDERS28
1.7SUMMARY OF CHANGES29
2RESEARCH METHODOLOGY30
2.1RESEARCH APPROACH30
FIGURE 2RESEARCH DESIGN30
2.1.1SECONDARY DATA31
2.1.2PRIMARY DATA32
FIGURE 3BREAKDOWN OF PRIMARY INTERVIEWS: STEM CELL THERAPY MARKET32
2.2MARKET SIZE ESTIMATION33
FIGURE 4MARKET SIZE ESTIMATION: BOTTOM-UP (SUPPLY SIDE): COLLECTIVE REVENUE OF STEM CELL THERAPY MARKET PLAYERS33
FIGURE 5MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS, 202134
FIGURE 6AVERAGE MARKET SIZE ESTIMATION, 202134
2.3GROWTH FORECAST36
FIGURE 7STEM CELL THERAPY MARKET: CAGR PROJECTIONS (2022–2027)36
FIGURE 8STEM CELL THERAPY MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, CHALLENGES, AND OPPORTUNITIES37
FIGURE 9MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH37
2.4DATA TRIANGULATION39
FIGURE 10DATA TRIANGULATION METHODOLOGY39
2.5PRIMARY INSIGHTS40
FIGURE 11MARKET VALIDATION FROM PRIMARY EXPERTS40
2.6RESEARCH ASSUMPTIONS40
2.7RISK ASSESSMENT41

3EXECUTIVE SUMMARY42
FIGURE 12STEM CELL THERAPY MARKET, BY TYPE, 2022 VS. 2027 (USD MILLION)42
FIGURE 13STEM CELL THERAPY MARKET, BY CELL SOURCE,
2022 VS. 2027 (USD MILLION)43
FIGURE 14STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION,
2022 VS. 2026 (USD MILLION)43
FIGURE 15GEOGRAPHICAL SNAPSHOT OF STEM CELL THERAPY MARKET44
4PREMIUM INSIGHTS46
4.1STEM CELL THERAPY MARKET OVERVIEW46
FIGURE 16INCREASING INVESTMENTS & FUNDING INITIATIVES FOR STEM CELL RESEARCH TO DRIVE MARKET GROWTH46
4.2NORTH AMERICA: STEM CELL THERAPY MARKET47
FIGURE 17ALLOGENEIC STEM CELL THERAPY TO COMMAND LARGEST SHARE IN 202147
4.3NORTH AMERICA: STEM CELL THERAPY MARKET, BY CELL SOURCE,
2022 VS. 2027 (USD MILLION)47
FIGURE 18BONE MARROW-DERIVED MSCS TO GROW AT HIGHEST CAGR DURING FORECAST PERIOD47
5MARKET OVERVIEW48
5.1INTRODUCTION48
FIGURE 19MARKET DYNAMICS: DRIVERS, OPPORTUNITIES, RESTRAINTS, AND CHALLENGES48
5.2MARKET DYNAMICS49
5.2.1DRIVERS49
5.2.1.1Availability of funding for stem cell research49
TABLE 1ICMR FUNDING FOR STEM CELL RESEARCH, 2019–2021 (USD)49
FIGURE 20STEM CELL RESEARCH FUNDING IN LAST 10 YEARS49
TABLE 2NIH FUNDING FOR CELL-BASED RESEARCH, 2016–2021 (USD MILLION)50
5.2.1.2Increasing GMP certification approvals for cell therapy production facilities50
TABLE 3NEW GMP FACILITIES, 2017-202051
5.2.1.3Increasing clinical trials for stem cell-based therapies51
FIGURE 21NUMBER OF CLINICAL TRIALS (2015-2020)51
FIGURE 22CLINICAL TRIALS, BY PHASE52
5.2.2RESTRAINTS52
5.2.2.1Ethical concerns related to embryonic stem cells52
5.2.2.2High cost of cell-based research52
5.2.3OPPORTUNITIES53
5.2.3.1Emergence of iPSCs as an alternative to ESCs53
5.2.3.2Growing demand for cell & gene therapies53
5.2.4CHALLENGES53
5.2.4.1Technical limitations associated with manufacturing processes53

5.3TECHNOLOGY ANALYSIS54
TABLE 4STEM CELL THERAPIES AND GENE THERAPIES54
5.4VALUE CHAIN ANALYSIS54
FIGURE 23VALUE CHAIN ANALYSIS OF STEM CELL THERAPY MARKET55
5.5ROLE IN ECOSYSTEM56
FIGURE 24ECOSYSTEM MARKET MAP56
5.6SUPPLY CHAIN ANALYSIS56
FIGURE 25SUPPLY CHAIN ANALYSIS OF STEM CELL THERAPY MARKET57
TABLE 5SUPPLY CHAIN ANALYSIS: COMMERCIAL SCALE/KEY MANUFACTURERS57
TABLE 6SUPPLY CHAIN ANALYSIS: PIPELINE/EMERGING MANUFACTURERS58
5.7PORTER’S FIVE FORCES ANALYSIS58
5.7.1THREAT OF NEW ENTRANTS59
5.7.2THREAT OF SUBSTITUTES59
5.7.3BARGAINING POWER OF SUPPLIERS59
5.7.4BARGAINING POWER OF BUYERS59
5.7.5INTENSITY OF COMPETITION RIVALRY60
5.8REGULATORY LANDSCAPE60
5.8.1NORTH AMERICA60
TABLE 7NORTH AMERICA: REGULATORY LANDSCAPE FOR STEM CELL THERAPIES60
5.8.2EUROPE62
TABLE 8EUROPE: REGULATORY LANDSCAPE FOR STEM CELL THERAPIES62
5.8.3ASIA PACIFIC63
TABLE 9ASIA PACIFIC: REGULATORY LANDSCAPE FOR STEM CELL THERAPIES63
5.8.4REST OF THE WORLD65
TABLE 10ROW: REGULATORY LANDSCAPE FOR STEM CELL THERAPIES65
5.9PRICING ANALYSIS66
5.9.1PRICING ANALYSIS66
TABLE 11AVERAGE SELLING PRICES OF KEY PLAYERS66
5.9.2AVERAGE SELLING PRICE TREND – STEM CELL THERAPY TREATMENT66
5.10PATENT ANALYSIS67
FIGURE 26PATENT ANALYSIS OF STEM CELL THERAPIES IN LAST 10 YEARS (2011-2020)67
5.11KEY CONFERENCES & EVENTS IN 2022–202367
5.11.1STEM CELL THERAPY CONFERENCES (2022–2023)67
TABLE 12STEM CELL THERAPY CONFERENCES (2022–2023)67
5.12DISRUPTIONS & TRENDS IMPACTING CUSTOMERS’ BUSINESSES68
5.13KEY STAKEHOLDERS AND BUYING CRITERIA68
FIGURE 27KEY STAKEHOLDERS IN STEM CELL THERAPY MARKET68
FIGURE 28KEY BUYING CRITERIA FOR END USERS69
FIGURE 29REVENUE SHIFT & NEW POCKET FOR STEM CELL THERAPY COMPANIES69

6STEM CELL THERAPY MARKET, BY TYPE70
6.1INTRODUCTION71
TABLE 13STEM CELL THERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION)71
6.2ALLOGENEIC STEM CELL THERAPY71
6.2.1FAVORABLE SCALING UP OF PRODUCTION PROCESSES TO DRIVE SEGMENT71
TABLE 14ALLOGENEIC STEM CELL THERAPY MARKET, BY REGION,
2020–2027 (USD MILLION)71
TABLE 15NORTH AMERICA: ALLOGENEIC STEM CELL THERAPY MARKET, BY COUNTRY, 2020–2027 (USD MILLION)72
TABLE 16EUROPE: ALLOGENEIC STEM CELL THERAPY MARKET, BY COUNTRY, 2020–2027 (USD MILLION)72
TABLE 17ASIA PACIFIC: ALLOGENEIC STEM CELL THERAPY MARKET, BY COUNTRY, 2020–2027 (USD MILLION)72
6.3AUTOLOGOUS STEM CELL THERAPY73
6.3.1LOW RISK OF POST-TREATMENT COMPLICATIONS TO DRIVE SEGMENT73
TABLE 18AUTOLOGOUS STEM CELL THERAPY MARKET, BY REGION,
2020–2027 (USD MILLION)73
TABLE 19NORTH AMERICA: AUTOLOGOUS STEM CELL THERAPY MARKET, BY COUNTRY, 2020–2027 (USD MILLION)73
TABLE 20EUROPE: AUTOLOGOUS STEM CELL THERAPY MARKET, BY COUNTRY,
2020–2027 (USD MILLION)74
TABLE 21ASIA PACIFIC: AUTOLOGOUS STEM CELL THERAPY MARKET, BY COUNTRY, 2020–2027 (USD MILLION)74
7STEM CELL THERAPY MARKET, BY CELL SOURCE75
7.1INTRODUCTION76
TABLE 22STEM CELL THERAPY MARKET, BY CELL SOURCE, 2020–2027 (USD MILLION)76
7.2ADIPOSE TISSUE-DERIVED MSCS76
7.2.1PROPERTIES SUCH AS SIMPLIFIED HARVESTING & EASE OF ISOLATION TO DRIVE MARKET76
TABLE 23STEM CELL THERAPY MARKET FOR ADIPOSE TISSUE-DERIVED MSCS, BY REGION, 2020–2027 (USD MILLION)77
TABLE 24NORTH AMERICA: STEM CELL THERAPY MARKET FOR ADIPOSE TISSUE-DERIVED MSCS, BY COUNTRY, 2020–2027 (USD MILLION)77
TABLE 25EUROPE: STEM CELL THERAPY MARKET FOR ADIPOSE-TISSUE DERIVED MSCS, BY COUNTRY, 2020–2027 (USD MILLION)77
TABLE 26ASIA PACIFIC: STEM CELL THERAPY MARKET FOR ADIPOSE-TISSUE DERIVED MSCS, BY COUNTRY, 2020–2027 (USD MILLION)78
7.3BONE MARROW-DERIVED MSCS78
7.3.1HIGH PREVALENCE OF METABOLIC DISORDERS TO DRIVE MARKET78
TABLE 27STEM CELL THERAPY MARKET FOR BONE MARROW-DERIVED MSCS, BY REGION, 2020–2027 (USD MILLION)79
TABLE 28NORTH AMERICA: STEM CELL THERAPY MARKET FOR BONE MARROW-DERIVED MSCS, BY COUNTRY, 2020–2027 (USD MILLION)79
TABLE 29EUROPE: STEM CELL THERAPY MARKET FOR BONE MARROW-DERIVED MSCS, BY COUNTRY, 2020–2027 (USD MILLION)79
TABLE 30ASIA PACIFIC: STEM CELL THERAPY MARKET FOR BONE MARROW-DERIVED MSCS, BY COUNTRY, 2020–2027 (USD MILLION)80
7.4PLACENTA/UMBILICAL CORD-DERIVED MSCS80
7.4.1LOWER CHANCES OF IMMUNE REJECTION TO SUPPORT MARKET80
TABLE 31STEM CELL THERAPY MARKET FOR PLACENTA/UMBILICAL CORD-DERIVED MSCS, BY REGION, 2020–2027 (USD MILLION)80
TABLE 32NORTH AMERICA: STEM CELL THERAPY MARKET FOR PLACENTA/UMBILICAL CORD-DERIVED MSCS, BY COUNTRY, 2020–2027 (USD MILLION)81
TABLE 33EUROPE: STEM CELL THERAPY MARKET FOR PLACENTA/UMBILICAL CORD-DERIVED MSCS, BY COUNTRY, 2020–2027 (USD MILLION)81
TABLE 34ASIA PACIFIC: STEM CELL THERAPY MARKET FOR PLACENTA/UMBILICAL CORD-DERIVED MSCS, BY COUNTRY, 2020–2027 (USD MILLION)81
7.5OTHER CELL SOURCES82
TABLE 35STEM CELL THERAPY MARKET FOR OTHER CELL SOURCES, BY REGION, 2020–2027 (USD MILLION)82
TABLE 36NORTH AMERICA: STEM CELL THERAPY MARKET FOR OTHER CELL SOURCES, BY COUNTRY, 2020–2027 (USD MILLION)82
TABLE 37EUROPE: STEM CELL THERAPY MARKET FOR OTHER CELL SOURCES,
BY COUNTRY, 2020–2027 (USD MILLION)83
TABLE 38ASIA PACIFIC: STEM CELL THERAPY MARKET FOR OTHER CELL SOURCES,
BY COUNTRY, 2020–2027 (USD MILLION)83
8STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION84
8.1INTRODUCTION85
TABLE 39STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD MILLION)85
8.2MUSCULOSKELETAL DISORDERS85
8.2.1RISING INCIDENCE OF OSTEOARTHRITIS TO DRIVE MARKET85
TABLE 40STEM CELL THERAPY MARKET FOR MUSCULOSKELETAL DISORDERS,
BY REGION, 2020–2027 (USD MILLION)86
TABLE 41NORTH AMERICA: STEM CELL THERAPY MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION)86
TABLE 42EUROPE: STEM CELL THERAPY MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION)86
TABLE 43ASIA PACIFIC: STEM CELL THERAPY MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION)87
8.3WOUNDS & INJURIES87
8.3.1GROWING BENEFITS OF ALLOGENEIC-BASED THERAPIES TO SUPPORT MARKET GROWTH87
TABLE 44STEM CELL THERAPY MARKET FOR WOUNDS & INJURIES,
BY REGION, 2020–2027 (USD MILLION)87
TABLE 45NORTH AMERICA: STEM CELL THERAPY MARKET FOR WOUNDS & INJURIES, BY COUNTRY, 2020–2027 (USD MILLION)88
TABLE 46EUROPE: STEM CELL THERAPY MARKET FOR WOUNDS & INJURIES,
BY COUNTRY, 2020–2027 (USD MILLION)88
TABLE 47ASIA PACIFIC: STEM CELL THERAPY MARKET FOR WOUNDS & INJURIES,
BY COUNTRY, 2020–2027 (USD MILLION)88

8.4INFLAMMATORY & AUTOIMMUNE DISEASES89
8.4.1INCREASING CLINICAL TRIALS FOR BONE MARROW-DERIVED MSCS TO SUPPORT MARKET GROWTH89
TABLE 48STEM CELL THERAPY MARKET FOR INFLAMMATORY & AUTOIMMUNE DISEASES, BY REGION, 2020–2027 (USD MILLION)89
TABLE 49NORTH AMERICA: STEM CELL THERAPY MARKET FOR INFLAMMATORY & AUTOIMMUNE DISEASES, BY COUNTRY, 2020–2027 (USD MILLION)89
TABLE 50EUROPE: STEM CELL THERAPY MARKET FOR INFLAMMATORY & AUTOIMMUNE DISEASES, BY COUNTRY, 2020–2027 (USD MILLION)90
TABLE 51ASIA PACIFIC: STEM CELL THERAPY MARKET FOR INFLAMMATORY & INFLAMMATORY DISEASES, BY COUNTRY, 2020–2027 (USD MILLION)90
8.5SURGERIES91
8.5.1GROWING CLINICAL RESEARCH FOR SURGICAL APPLICATIONS TO SUPPORT MARKET GROWTH91
TABLE 52STEM CELL THERAPY MARKET FOR SURGERIES, BY REGION,
2020–2027 (USD MILLION)91
TABLE 53NORTH AMERICA: STEM CELL THERAPY MARKET FOR SURGERIES,
BY COUNTRY, 2020–2027 (USD MILLION)91
TABLE 54EUROPE: STEM CELL THERAPY MARKET FOR SURGERIES, BY COUNTRY, 2020–2027 (USD MILLION)92
TABLE 55ASIA PACIFIC: STEM CELL THERAPY MARKET FOR SURGERIES, BY COUNTRY, 2020–2027 (USD MILLION)92
8.6CARDIOVASCULAR DISEASES92
8.6.1RISING DEMAND FOR CVD TREATMENTS TO SUPPORT MARKET GROWTH92
TABLE 56STEM CELL THERAPY MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2020–2027 (USD MILLION)93
TABLE 57NORTH AMERICA: STEM CELL THERAPY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2020–2027 (USD MILLION)93
TABLE 58EUROPE: STEM CELL THERAPY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2020–2027 (USD MILLION)93
TABLE 59ASIA PACIFIC: STEM CELL THERAPY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2020–2027 (USD MILLION)94
8.7NEUROLOGICAL DISORDERS94
8.7.1RISING PREVALENCE OF NEUROGENERATIVE DISORDERS TO SUPPORT MARKET GROWTH94
TABLE 60STEM CELL THERAPY MARKET FOR NEUROLOGICAL DISORDERS, BY REGION, 2020–2027 (USD MILLION)94
TABLE 61NORTH AMERICA: STEM CELL THERAPY MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION)95
TABLE 62EUROPE: STEM CELL THERAPY MARKET FOR NEUROLOGICAL DISORDERS,
BY COUNTRY, 2020–2027 (USD MILLION)95
TABLE 63ASIA PACIFIC: STEM CELL THERAPY MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION)95
8.8OTHER THERAPEUTIC APPLICATIONS96
TABLE 64STEM CELL THERAPY FOR OTHER THERAPEUTIC APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)96
TABLE 65NORTH AMERICA: STEM CELL THERAPY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)96
TABLE 66EUROPE: STEM CELL THERAPY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)97
TABLE 67ASIA PACIFIC: STEM CELL THERAPY FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)97
9STEM CELL THERAPY MARKET, BY REGION98
9.1INTRODUCTION99
TABLE 68STEM CELL THERAPY MARKET, BY REGION, 2020–2027 (USD MILLION)99
9.2NORTH AMERICA99
FIGURE 30NORTH AMERICA: STEM CELL THERAPY MARKET SNAPSHOT100
TABLE 69NORTH AMERICA: STEM CELL THERAPY MARKET, BY COUNTRY,
2020–2027 (USD MILLION)100
TABLE 70NORTH AMERICA: STEM CELL THERAPY MARKET, BY CELL SOURCE,
2020–2027 (USD MILLION)101
TABLE 71NORTH AMERICA: STEM CELL THERAPY MARKET, BY TYPE,
2020–2027 (USD MILLION)101
TABLE 72NORTH AMERICA: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD MILLION)101
9.2.1US102
9.2.1.1Rising approvals for stem cell therapy products to drive market102
FIGURE 31NIH FUNDING IN LAST 10 YEARS (2011–2021)102
TABLE 73US: STEM CELL THERAPY MARKET, BY CELL SOURCE,
2020–2027 (USD MILLION)102
TABLE 74US: STEM CELL THERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION)103
TABLE 75US: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION,
2020–2027 (USD MILLION)103
9.2.2CANADA103
9.2.2.1Increasing government focus on targeted stem cell therapy treatment to drive market103
TABLE 76CANADA: STEM CELL THERAPY MARKET, BY CELL SOURCE,
2020–2027 (USD MILLION)104
TABLE 77CANADA: STEM CELL THERAPY MARKET, BY TYPE,
2020–2027 (USD MILLION)104
TABLE 78CANADA: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD MILLION)105
9.3EUROPE105
TABLE 79EUROPE: STEM CELL THERAPY MARKET, BY COUNTRY,
2020–2027 (USD MILLION)105
TABLE 80EUROPE: STEM CELL THERAPY MARKET, BY CELL SOURCE,
2020–2027 (USD MILLION)106
TABLE 81EUROPE: STEM CELL THERAPY MARKET, BY TYPE,
2020–2027 (USD MILLION)106
TABLE 82EUROPE: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD MILLION)106
9.3.1GERMANY107
9.3.1.1Strong R&D base and growing focus on minimally invasive treatments to drive market107
TABLE 83GERMANY: STEM CELL THERAPY MARKET, BY CELL SOURCE,
2020–2027 (USD MILLION)107
TABLE 84GERMANY: STEM CELL THERAPY MARKET, BY TYPE,
2020–2027 (USD MILLION)107
TABLE 85GERMANY: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD MILLION)108
9.3.2UK108
9.3.2.1Rising adoption of cell-based therapies to drive market108
TABLE 86UK: STEM CELL THERAPY MARKET, BY CELL SOURCE,
2020–2027 (USD MILLION)109
TABLE 87UK: STEM CELL THERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION)109
TABLE 88UK: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION,
2020–2027 (USD MILLION)109
9.3.3FRANCE110
9.3.3.1Rising healthcare expenditure to support uptake of stem cell therapy products110
TABLE 89FRANCE: STEM CELL THERAPY MARKET, BY CELL SOURCE,
2020–2027 (USD MILLION)110
TABLE 90FRANCE: STEM CELL THERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION)110
TABLE 91FRANCE: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD MILLION)111
9.3.4REST OF EUROPE111
TABLE 92REST OF EUROPE: STEM CELL THERAPY MARKET, BY CELL SOURCE,
2020–2027 (USD MILLION)111
TABLE 93REST OF EUROPE: STEM CELL THERAPY MARKET, BY TYPE,
2020–2027 (USD MILLION)112
TABLE 94REST OF EUROPE: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD MILLION)112
9.4ASIA PACIFIC113
FIGURE 32ASIA PACIFIC: STEM CELL THERAPY MARKET SNAPSHOT113
TABLE 95ASIA PACIFIC: STEM CELL THERAPY MARKET, BY CELL SOURCE,
2020–2027 (USD MILLION)114
TABLE 96ASIA PACIFIC: STEM CELL THERAPY MARKET, BY TYPE,
2020–2027 (USD MILLION)114
TABLE 97ASIA PACIFIC: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD MILLION)114
9.4.1JAPAN115
9.4.1.1Growing geriatric population and rapid regulatory processes to drive market115
TABLE 98JAPAN: STEM CELL THERAPY MARKET, BY CELL SOURCE,
2020–2027 (USD MILLION)115
TABLE 99JAPAN: STEM CELL THERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION)115
TABLE 100JAPAN: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD MILLION)116
9.4.2SOUTH KOREA116
9.4.2.1Favorable government support for stem cell therapy products to support market growth116
TABLE 101SOUTH KOREA: STEM CELL THERAPY MARKET, BY CELL SOURCE,
2020–2027 (USD MILLION)116
TABLE 102SOUTH KOREA: STEM CELL THERAPY MARKET, BY TYPE,
2020–2027 (USD MILLION)117
TABLE 103SOUTH KOREA: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD MILLION)117
9.4.3INDIA117
9.4.3.1Rising cases of neurodegenerative disorders drive market117
TABLE 104INDIA: STEM CELL THERAPY MARKET, BY CELL SOURCE,
2020–2027 (USD MILLION)118
TABLE 105INDIA: STEM CELL THERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION)118
TABLE 106INDIA: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION,
2020–2027 (USD MILLION)118
9.4.4REST OF ASIA PACIFIC119
TABLE 107REST OF ASIA PACIFIC: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2020–2027 (USD MILLION)119
TABLE 108REST OF ASIA PACIFIC: STEM CELL THERAPY MARKET, BY TYPE,
2020–2027 (USD MILLION)119
TABLE 109REST OF ASIA PACIFIC: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD MILLION)120
9.5REST OF THE WORLD120
TABLE 110REST OF THE WORLD: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2020–2027 (USD MILLION)121
TABLE 111REST OF THE WORLD: STEM CELL THERAPY MARKET, BY TYPE,
2020–2027 (USD MILLION)121
TABLE 112REST OF THE WORLD: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD MILLION)121
10COMPETITIVE LANDSCAPE122
10.1INTRODUCTION122
10.2STRATEGIES ADOPTED BY KEY PLAYERS/RIGHT TO WIN122
FIGURE 33STEM CELL THERAPY MARKET: STRATEGIES ADOPTED123
10.3REVENUE SHARE ANALYSIS123
10.4MARKET SHARE ANALYSIS (2021)124
10.5COMPANY EVALUATION QUADRANT (KEY MARKET PLAYERS)125
10.5.1STARS126
10.5.2EMERGING LEADERS126
10.5.3PERVASIVE PLAYERS126
10.5.4PARTICIPANTS126
FIGURE 36STEM CELL THERAPY MARKET: COMPANY EVALUATION QUADRANT FOR APPROVED PRODUCTS (2021)127
10.6COMPETITIVE BENCHMARKING128
10.6.1STEM CELL THERAPY MARKET: A DETAILED LIST OF STARTUPS/SMES128
TABLE 113STEM CELL THERAPY MARKET: DETAILED LIST OF STARTUPS/SMES128
10.6.2STEM CELL THERAPY MARKET: COMPETITIVE BENCHMARKING OF OTHER PLAYERS [STARTUPS/SMES)129
TABLE 114STEM CELL THERAPY MARKET: COMPETITIVE BENCHMARKING OF OTHER PLAYERS [STARTUPS/SMES]129
10.7COMPANY EVALUATION QUADRANT (SMES/START-UPS)130
10.7.1PROGRESSIVE COMPANIES130
10.7.2STARTING BLOCKS130
10.7.3RESPONSIVE COMPANIES130
10.7.4DYNAMIC COMPANIES130
FIGURE 37STEM CELL THERAPY MARKET: COMPANY EVALUATION QUADRANT FOR PRODUCTS UNDER PIPELINE (2021)131
10.8COMPANY PRODUCT FOOTPRINT ANALYSIS132
TABLE 115COMPANY PRODUCT FOOTPRINT132
10.9COMPANY FOOTPRINT OF MAJOR PLAYERS133
TABLE 116COMPANY REGIONAL FOOTPRINT133
10.10COMPETITIVE SCENARIO134
TABLE 117STEM CELL THERAPY MARKET: REGULATORY APPROVALS134
TABLE 118STEM CELL THERAPY MARKET: DEALS134
11COMPANY PROFILES135
11.1MAJOR PLAYERS135
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
11.1.1SMITH+NEPHEW135
TABLE 119SMITH+NEPHEW: BUSINESS OVERVIEW135
FIGURE 38SMITH+NEPHEW: COMPANY SNAPSHOT (2021)136
TABLE 120SMITH+NEPHEW: PRODUCT OFFERINGS136
TABLE 121SMITH+NEPHEW: DEALS137
11.1.2MEDIPOST CO., LTD.138
TABLE 122MEDIPOST CO., LTD: BUSINESS OVERVIEW138
FIGURE 39MEDIPOST CO., LTD: COMPANY SNAPSHOT (2019)138
TABLE 123MEDIPOST CO., LTD: PRODUCT OFFERINGS139
TABLE 124MEDIPOST CO., LTD: PRODUCT APPROVALS139
TABLE 125MEDIPOST CO., LTD: DEALS139
TABLE 126MEDIPOST CO., LTD: OTHERS139
TABLE 127MEDIPOST CO., LTD: REGULATORY APPROVALS AND PATENTS140
11.1.3JCR PHARMACEUTICALS CO., LTD.141
TABLE 128JCR PHARMACEUTICALS CO., LTD: BUSINESS OVERVIEW141
FIGURE 40JCR PHARMACEUTICALS CO., LTD: COMPANY SNAPSHOT (2021)141
TABLE 129JCR PHARMACEUTICALS CO., LTD: PRODUCT OFFERINGS142
11.1.4TAKEDA PHARMACEUTICAL COMPANY LIMITED143
TABLE 130TAKEDA PHARMACEUTICAL COMPANY LIMITED: BUSINESS OVERVIEW143
FIGURE 41TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY SNAPSHOT (2021)143
TABLE 131TAKEDA PHARMACEUTICAL COMPANY LIMITED: PRODUCT OFFERINGS144
TABLE 132TAKEDA PHARMACEUTICAL COMPANY LIMITED: EXPANSIONS144
TABLE 133TAKEDA PHARMACEUTICAL COMPANY LIMITED: REGULATORY APPROVALS144
11.1.5ANTEROGEN. CO., LTD.145
TABLE 134ANTEROGEN CO., LTD: BUSINESS OVERVIEW145
TABLE 135ANTEROGEN CO., LTD: PRODUCT OFFERINGS145
11.1.6CORESTEM146
TABLE 136CORESTEM: BUSINESS OVERVIEW146
TABLE 137CORESTEM: PRODUCT OFFERINGS146
TABLE 138CORESTEM: REGULATORY APPROVALS146
11.1.7PHARMICELL CO., LTD.147
TABLE 139PHARMICELL CO., LTD.: BUSINESS OVERVIEW147
TABLE 140PHARMICELL CO., LTD.: PRODUCT OFFERINGS147
TABLE 141PHARMICELL CO., LTD.: DEALS147
11.1.8NUVASIVE, INC.148
TABLE 142NUVASIVE, INC: BUSINESS OVERVIEW148
FIGURE 42NUVASIVE, INC: COMPANY SNAPSHOT (2021)149
TABLE 143NUVASIVE, INC.: PRODUCT OFFERINGS149
11.1.9RTI SURGICAL150
TABLE 144RTI SURGICAL: BUSINESS OVERVIEW150
TABLE 145RTI SURGICAL: PRODUCT OFFERINGS150
11.1.10ALLOSOURCE151
TABLE 146ALLOSOURCE: BUSINESS OVERVIEW151
TABLE 147ALLOSOURCE: PRODUCT OFFERINGS151
11.1.11HOLOSTEM TERAPIE AVANZATE SRL152
TABLE 148HOLOSTEM TERAPIE AVANZATE SRL: BUSINESS OVERVIEW152
TABLE 149HOLOSTEM TERAPIE AVANZATE SRL: PRODUCT OFFERINGS152
11.1.12ORTHOFIX153
TABLE 150ORTHOFIX: BUSINESS OVERVIEW153
FIGURE 43ORTHOFIX: COMPANY SNAPSHOT (2021)154
TABLE 151ORTHOFIX: PRODUCT OFFERINGS154
11.1.13STEMPEUTICS RESEARCH155
TABLE 152STEMPEUTICS RESEARCH: BUSINESS OVERVIEW155
TABLE 153STEMPEUTICS RESEARCH: PRODUCT OFFERINGS155
11.1.14REGROW BIOSCIENCES PVT LTD.156
TABLE 154REGROW BIOSCIENCES PVT LTD: BUSINESS OVERVIEW156
TABLE 155REGROW BIOSCIENCES PVT LTD: PRODUCT OFFERINGS156
11.2OTHER PLAYERS (PRODUCTS IN PIPELINE)157
11.2.1ATHERSYS, INC.157
11.2.2MESOBLAST LTD157
11.2.3BIORESTORATIVE THERAPIES, INC.158
11.2.4PLURISTEM INC.158
11.2.5BRAINSTORM CELL LIMITED.158
11.2.6GAMIDA CELL159
11.2.7VIACYTE, INC.159
11.2.8KANGSTEM BIOTECH159
11.2.9HOPE BIOSCIENCES160
11.2.10CELLULAR BIOMEDICINE GROUP (CBMG)160
11.2.11PERSONALIZED STEM CELLS160
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
12APPENDIX161
12.1DISCUSSION GUIDE161
12.2KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL163
12.3CUSTOMIZATION OPTIONS165
12.4RELATED REPORTS165
12.5AUTHOR DETAILS166

Report Title: Stem Cell Therapy Market by Type (Allogeneic, Autologous), Cell Source (Adipose Tissue-derived MSC, Bone Marrow, Placenta/Umbilical Cord), Therapeutic Application (Musculoskeletal, Wounds, Surgeries, Cardiovascular, Neurological) - Global Forecast to 2027


Your Details
Valid Invalid number

SELECT A FORMAT

ADD TO CART BUY NOW

Related Report

UAE Ultrasound Systems Market By Technology (Diagnostic Ultrasound {2D Ultrasound, 3D & 4D Ultrasound, Doppler Ultrasound} v/s Therapeutic Ultrasound {High-Intensity Focused Ultrasound (HIFU) v/s Extracorporeal Shockwave Lithotripsy (ESWL)}), By Display Type (Black & White v/s Colored), By Mobility (Fixed v/s Mobile), By Application (General Imaging, Obstetrics/Gynecology, Cardiology, Urology, Orthopedic & Musculoskeletal, Others), By End User (Hospitals & Clinics, Diagnostic Centers, Ambulatory Care Centers, Others), By Region, Competition Forecast & Opportunities, 2027

UAE Ultrasound Systems Market By Technology (Diagnostic Ultrasound {2D Ultrasound, 3D & 4D Ultrasound, Doppler Ultrasound} v/s Therapeutic Ultrasound {High-Intensity Focused Ultrasound (HIFU) v/s Extracorporeal Shockwave Lithotripsy (ESWL)}), By Display Type (Black & White v/s Colored), By Mobility (Fixed v/s Mobile), By Application (General Imaging, Obstetrics/Gynecology, Cardiology, Urology, Orthopedic & Musculoskeletal, Others), By End User (Hospitals & Clinics, Diagnostic Centers, Ambulatory Care Centers, Others), By Region, Competition Forecast & Opportunities, 2027

UAE Syringe Market By Product Type (General {Insulin, Allergy, Tuberculin, Others}, Specialized {Auto-Disable, Active Safety, Passive Safety}, Smart), By Material (Plastic, Glass, Others), By Usage (Reusable v/s Disposable), By End User (Hospitals & Clinics, Blood Collection Centers, Diabetes Care Centers, Others), By Region, Competition Forecast & Opportunities, 2027

UAE Syringe Market By Product Type (General {Insulin, Allergy, Tuberculin, Others}, Specialized {Auto-Disable, Active Safety, Passive Safety}, Smart), By Material (Plastic, Glass, Others), By Usage (Reusable v/s Disposable), By End User (Hospitals & Clinics, Blood Collection Centers, Diabetes Care Centers, Others), By Region, Competition Forecast & Opportunities, 2027

UAE Surgical Scrubs Market By Type (Reusable v/s Disposable), By Distribution Channel (Direct Sales, Distributors/Suppliers, Online), By End User (Hospitals, Cardiac Care Centers, Ambulatory Surgical Centers), By Region, Competition Forecast & Opportunities, 2027

UAE Surgical Scrubs Market By Type (Reusable v/s Disposable), By Distribution Channel (Direct Sales, Distributors/Suppliers, Online), By End User (Hospitals, Cardiac Care Centers, Ambulatory Surgical Centers), By Region, Competition Forecast & Opportunities, 2027

UAE Stent Market By Product Type (Vascular Stents {Coronary Stents, Peripheral Stents, Neurovascular Stents} v/s Non-Vascular Stents {Gastrointestinal Stents, Urological Stents, Pulmonary (Airway) Stents}), By Material Type (Metal v/s Polymer), By Type (Balloon Expandable v/s Self-Expandable), By End User (Hospitals & Clinics, Ambulatory Care Centers, Others), By Region, Competition Forecast & Opportunities, 2027

UAE Stent Market By Product Type (Vascular Stents {Coronary Stents, Peripheral Stents, Neurovascular Stents} v/s Non-Vascular Stents {Gastrointestinal Stents, Urological Stents, Pulmonary (Airway) Stents}), By Material Type (Metal v/s Polymer), By Type (Balloon Expandable v/s Self-Expandable), By End User (Hospitals & Clinics, Ambulatory Care Centers, Others), By Region, Competition Forecast & Opportunities, 2027

UAE Respiratory Care Devices Market By Product Type (Therapeutic Devices {Ventilators, Pap Devices, Nebulizers, Oxygen Concentrators, Humidifiers, Inhalers, Others}, Monitoring Devices {Pulse Oximeters, Gas Analyzers, Capnographs}, Diagnostic Devices {Spirometers, Peak Flow Meters, Polysomnography (PSG) Devices}, Consumables & Accessories {Masks, Breathing Circuits, Disposable Resuscitators, Others}), By Indication (Chronic Obstructive Pulmonary Disease, Sleep Apnea, Asthma, Infectious Diseases, Others), By End User (Hospitals & Clinics, Ambulatory Care Centers, Others), By Region, Competition Forecast & Opportunities, 2027

UAE Respiratory Care Devices Market By Product Type (Therapeutic Devices {Ventilators, Pap Devices, Nebulizers, Oxygen Concentrators, Humidifiers, Inhalers, Others}, Monitoring Devices {Pulse Oximeters, Gas Analyzers, Capnographs}, Diagnostic Devices {Spirometers, Peak Flow Meters, Polysomnography (PSG) Devices}, Consumables & Accessories {Masks, Breathing Circuits, Disposable Resuscitators, Others}), By Indication (Chronic Obstructive Pulmonary Disease, Sleep Apnea, Asthma, Infectious Diseases, Others), By End User (Hospitals & Clinics, Ambulatory Care Centers, Others), By Region, Competition Forecast & Opportunities, 2027

UAE Pregnancy Testing Kits Market By Product Type (Line Indicators {Strips, Cassettes, Mid-stream Devices}, Digital Devices, Others), By Type of Test (Urine Test for HCG, Blood Test for HCG, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region, Competition Forecast & Opportunities, 2027

UAE Pregnancy Testing Kits Market By Product Type (Line Indicators {Strips, Cassettes, Mid-stream Devices}, Digital Devices, Others), By Type of Test (Urine Test for HCG, Blood Test for HCG, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region, Competition Forecast & Opportunities, 2027